Get the Stockscreener App
473.66
0.52%
-2.47
After Hours:
473.66
United Therapeutics Corp stock is traded at $473.66, with a volume of 258.64K.
It is down -0.52% in the last 24 hours and down -0.67% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$476.13
Open:
$478.9
24h Volume:
258.64K
Relative Volume:
0.67
Market Cap:
$20.39B
Revenue:
$3.13B
Net Income/Loss:
$1.27B
P/E Ratio:
17.95
EPS:
26.3851
Net Cash Flow:
$1.12B
1W Performance:
-2.41%
1M Performance:
-0.67%
6M Performance:
+52.93%
1Y Performance:
+27.86%
1-Day Range:
$471.00
$484.98
1-Week Range:
$464.44
$486.25
52-Week Range:
$266.98
$519.99
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
MidWestOne Financial Group Inc. Raises Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Envestnet Asset Management Inc. Sells 15,252 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Can United Therapeutics Corporation navigate macro headwindsTrade Risk Summary & High Return Stock Watch Alerts - mfd.ru
Can United Therapeutics Corporation be recession proof2025 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
LSV Asset Management Sells 177,913 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp. (NASDAQ:UTHR) Passes the "Caviar Cruise" Quality Investing Screen - ChartMill
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026 - Stock Titan
United Therapeutics (NASDAQ:UTHR) COO Sells $10,679,625.00 in Stock - MarketBeat
United Therapeutics Nears Key Data Milestone With Completed TETON-1 IPF Trial - TipRanks
United Therapeutics Corporation $UTHR Shares Sold by Ashton Thomas Private Wealth LLC - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Cuts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data - simplywall.st
Aug Fed Impact: Will United Therapeutics Corporation benefit from government policyJuly 2025 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
United Therapeutics Corporation $UTHR Shares Purchased by AE Wealth Management LLC - MarketBeat
Mediolanum International Funds Ltd Sells 4,275 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring A 13% Upside Potential - DirectorsTalk Interviews
Bank of New York Mellon Corp Sells 11,016 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Summit Global Investments Sells 3,327 Shares of United Therapeutics Corporation $UTHR - MarketBeat
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Yahoo Finance
A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Finviz
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) - Finviz
Mutual of America Capital Management LLC Acquires 4,036 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 13,401 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Strs Ohio Has $4.22 Million Stake in United Therapeutics Corporation $UTHR - MarketBeat
What's Going On With United Therapeutics Stock Monday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics reports positive phase 1 results for bioengineered liver By Investing.com - Investing.com Canada
How Investors May Respond To United Therapeutics (UTHR) Positive Early Data For Bioengineered Liver Support Device - Yahoo Finance
United Therapeutics reports positive phase 1 results for bioengineered liver - Investing.com
Retirement Systems of Alabama Sells 18,709 Shares of United Therapeutics Corporation $UTHR - MarketBeat
World’s first FDA-cleared bioengineered liver trial meets survival goal - Stock Titan
The Best Pharma Stock I’ve Ever Seen - Nanalyze
United Therapeutics appoints biomedical research leader to board By Investing.com - Investing.com Nigeria
United Therapeutics Appoints Kevin J. Tracey To Board - citybiz
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to Board of Directors, Effective January 21, 2026 - marketscreener.com
United Therapeutics appoints biomedical research leader to board - Investing.com
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors - United Therapeutics Investor Relations
Element Squared LLC Buys 5,027 Shares of United Therapeutics Corp (UTHR) - GuruFocus
Marquette Asset Management, LLC Buys 1 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corporation (UTHR): A Bull Case Theory - Finviz
Polaris Capital Management LLC Sells 5,600 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Reassessing United Therapeutics (UTHR) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
United Therapeutics COO sells $10.7 million in UTHR stock - Investing.com
United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension - TipRanks
United Therapeutics Corporation $UTHR Shares Sold by State of Alaska Department of Revenue - MarketBeat
SG Americas Securities LLC Purchases 7,483 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Position Decreased by Nepsis Inc. - MarketBeat
How United Therapeutics Corporation (UTH) stock expands through international marketsTreasury Yields & Verified Swing Trading Watchlists - Улправда
Is United Therapeutics Corporation stock a good choice for value investorsJuly 2025 Recap & AI Enhanced Execution Alerts - Улправда
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):